Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
47 hedge funds and large institutions have $33.6M invested in Soleno Therapeutics in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 26 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.89% less ownership
Funds ownership: 40.99% → 37.1% (-3.9%)
18% less capital invested
Capital invested by funds: $41.2M → $33.6M (-$7.56M)
25% less funds holding
Funds holding: 63 → 47 (-16)
44% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 18
45% less call options, than puts
Call options by funds: $346K | Put options by funds: $634K
62% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.19M |
| 2 |
OC
Oppenheimer & Co
New York
|
+$472K |
| 3 |
Renaissance Technologies
New York
|
+$421K |
| 4 |
SG Americas Securities
New York
|
+$337K |
| 5 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$336K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.35M |
| 2 |
State Street
Boston,
Massachusetts
|
-$705K |
| 3 |
AIC
AWM Investment Company
New York
|
-$632K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$563K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$468K |
SLNO Hedge Fund Activity: Q2 2021 in Review
47 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2021, worth a combined $33.6M — down 18% from $41.2M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of SLNO and 10 opened new positions — a net loss of 16 holders — while 18 trimmed existing stakes and 10 added.
The largest buyer was Nantahala Capital Management, adding an estimated $2.19M. The largest seller was BlackRock, cutting an estimated $3.35M.
- 47 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2021, down from 63 in Q1 2021.
- Funds reported $33.6M of Soleno Therapeutics stock for Q2 2021, down 18% quarter-over-quarter.
- 10 funds opened new Soleno Therapeutics positions in Q2 2021 and 26 closed out, a net change of -16 holders.
- The largest Soleno Therapeutics buyer in Q2 2021 was Nantahala Capital Management, an estimated $2.19M added.
- The largest Soleno Therapeutics seller in Q2 2021 was BlackRock, an estimated $3.35M sold.
Based on aggregated 13F filings for Q2 2021.